Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study C Zoccali, SM Bode-Böger, F Mallamaci, FA Benedetto, G Tripepi, ... The Lancet 358 (9299), 2113-2117, 2001 | 1353 | 2001 |
Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease C Zoccali, F Mallamaci, S Parlongo, S Cutrupi, FA Benedetto, G Tripepi, ... Circulation 105 (11), 1354-1359, 2002 | 761 | 2002 |
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression C Zoccali, FA Benedetto, F Mallamaci, G Tripepi, G Giacone, ... Kidney international 65 (4), 1492-1498, 2004 | 473 | 2004 |
Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases T Tsuruda, G Boerrigter, BK Huntley, JA Noser, A Cataliotti, ... Circulation research 91 (12), 1127-1134, 2002 | 462 | 2002 |
Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients C Zoccali, F Mallamaci, FA Benedetto, G Tripepi, S Parlongo, A Cataliotti, ... Journal of the American Society of Nephrology 12 (7), 1508-1515, 2001 | 442 | 2001 |
Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis C Zoccali, FA Benedetto, F Mallamaci, G Tripepi, G Giacone, A Cataliotti, ... Journal of the American Society of Nephrology 12 (12), 2768-2774, 2001 | 400 | 2001 |
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients F Mallamaci, C Zoccali, G Tripepi, I Fermo, FA Benedetto, A Cataliotti, ... Kidney international 61 (2), 609-614, 2002 | 396 | 2002 |
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics S Mangiafico, LC Costello-Boerrigter, IA Andersen, A Cataliotti, ... European heart journal 34 (12), 886-893, 2013 | 369 | 2013 |
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients C Zoccali, F Mallamaci, R Maas, FA Benedetto, G Tripepi, LS Malatino, ... Kidney international 62 (1), 339-345, 2002 | 325 | 2002 |
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling A Cataliotti, LS Malatino, M Jougasaki, C Zoccali, P Castellino, G Giacone, ... Mayo Clinic Proceedings 76 (11), 1111-1119, 2001 | 316 | 2001 |
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure AM Hawkridge, DM Heublein, HR Bergen III, A Cataliotti, JC Burnett Jr, ... Proceedings of the National Academy of Sciences 102 (48), 17442-17447, 2005 | 314 | 2005 |
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients C Zoccali, FA Benedetto, F Mallamaci, G Tripepi, G Giacone, A Cataliotti, ... Journal of the American Society of Nephrology 15 (4), 1029-1037, 2004 | 267 | 2004 |
Diagnostic potential of cardiac natriuretic peptides in dialysis patients F Mallamaci, C Zoccali, G Tripepi, FA Benedetto, S Parlongo, A Cataliotti, ... Kidney international 59 (4), 1559-1566, 2001 | 227 | 2001 |
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure PM McKie, RJ Rodeheffer, A Cataliotti, FL Martin, LH Urban, ... Hypertension 47 (5), 874-880, 2006 | 226 | 2006 |
Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients F Mallamaci, C Zoccali, S Parlongo, G Tripepi, FA Benedetto, S Cutrupi, ... American journal of kidney diseases 40 (1), 68-75, 2002 | 210 | 2002 |
Norepinephrine and concentric hypertrophy in patients with end-stage renal disease C Zoccali, F Mallamaci, G Tripepi, S Parlongo, S Cutrupi, FA Benedetto, ... Hypertension 40 (1), 41-46, 2002 | 169 | 2002 |
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure A Cataliotti, G Boerrigter, LC Costello-Boerrigter, JA Schirger, T Tsuruda, ... Circulation 109 (13), 1680-1685, 2004 | 161 | 2004 |
Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor T Tsuruda, M Jougasaki, G Boerrigter, BK Huntley, HH Chen, ... Circulation research 90 (2), 128-134, 2002 | 158 | 2002 |
The prognostic value of N-terminal pro–B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects PM McKie, A Cataliotti, BD Lahr, FL Martin, MM Redfield, KR Bailey, ... Journal of the American college of cardiology 55 (19), 2140-2147, 2010 | 156 | 2010 |
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP F Macheret, D Heublein, LC Costello-Boerrigter, G Boerrigter, P McKie, ... Journal of the American College of Cardiology 60 (16), 1558-1565, 2012 | 138 | 2012 |